478028-23-8

Basic information

• Product Name: 2-Thiophenecarboxylic acid, 3-bromo-5-phenyl-, methyl ester
• CAS NO: 478028-23-8
• Molecular Formula: C12H9BrO2S
• Molecular Weight: 297.172
• Mol File: 478028-23-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-Thiophenecarboxylic acid, 3-bromo-5-phenyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiophenecarboxylic acid, 3-bromo-5-phenyl-, methyl ester(478028-23-8)
• EPA Substance Registry System: 2-Thiophenecarboxylic acid, 3-bromo-5-phenyl-, methyl ester(478028-23-8)

Safety Data

• Hazardous Substances Data: 478028-23-8(Hazardous Substances Data)

Upstream product

• 62224-21-9 3,5-dibromo-thiophene-2-carboxylic acid methyl ester 
• 98-80-6 phenylboronic acid 
• 100063-22-7 methyl 3-amino-5-phenylthiophene-2-carboxylate 

Downstream Products

• 1355040-82-2 methyl 3-((2-morpholino-2-oxoethyl)amino)-5-phenylthiophene-2-carboxylate 
• 1356457-08-3 (R)-3-cyclohexyl-4-(2-methoxycarbonyl-5-phenylthiophen-3-yl)-5-oxopiperazine-1-carboxylic acid tert-butyl ester 
• 1356457-10-7 3-((R)-2-cyclohexyl-6-oxopiperazin-1-yl)-5-phenylthiophene-2-carboxylic acid hydrochloride 
• 1356453-54-7 (R)-4-(2-carboxy-5-phenylthiophen-3-yl)-3-cyclohexyl-5-oxopiperazine-1-carboxylic acid tert-butyl ester 
• 712353-38-3 3-(N',N'-dimethyl-hydrazino)-5-phenyl-thiophene-2-carboxylic acid methyl ester 

Relevant articles and documents

COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

A compound is represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.